ERBB2 and breast carcinoma: On the other hand, the data available did not allow us to investigate survival by molecular subtype of breast cancer (e.g., luminal A or B, triple negative, HER2), but evidence suggests that the prognostic value of molecular subtype persists when adjusting for age, stage and histological grade, and certain subtypes may metastasized even when the tumor itself is localized [32].